Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis
Keywords:
tildrakizumab, psoriatic arthritis, psoriasis, psoriasis treatmentReferences
1. Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019 Sep; 206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6. PMID: 30196070; PMCID: PMC6401348.
2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.
2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.
Published
2022-05-02
Issue
Section
Research Letter
License
Copyright (c) 2022 Dario Buononato, gaetano licata, alessio gambardella, alina de rosa, giulia calabrese, giuseppe argenziano
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
1.
Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis. Dermatol Pract Concept [Internet]. 2022 May 2 [cited 2024 Mar. 29];12(2):e2022049. Available from: https://dpcj.org/index.php/dpc/article/view/1879